A supply chain security blueprint from the US association for generic and biosimilar drug manufacturers lays out an agenda Congress could adopt to build on the work it did in the CARES Act to eliminate drug shortages.
The measures the Association for Accessible Medicines proposed 30 April could find their way into additional coronavirus legislation or perhaps infrastructure or health care bills, AAM’s interim CEO
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?